Acrivon Therapeutics (ACRV) grants 49,830 RSUs to Chief Legal Officer Mary Miller

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Miller Mary reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics Chief Legal Officer Mary Miller received an equity award of 49,830 shares of Common Stock in the form of restricted stock units (RSUs). The grant was made at no cash cost to her and is compensation-related rather than an open-market transaction.

The RSUs vest over time. According to the terms, 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments after that date, as long as she continues in service. Following this grant, she directly holds 82,767 shares of Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Miller Mary

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	49,830	$0.00	--

Holdings After Transaction: Common Stock — 82,767 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 49,830 RSUs Shares after transaction: 82,767 shares Initial vesting portion: 16.67% of RSUs +2 more

5 metrics

RSUs granted 49,830 RSUs Grant to Chief Legal Officer on May 18, 2026

Shares after transaction 82,767 shares Total direct holdings following RSU grant

Initial vesting portion 16.67% of RSUs Vests on November 18, 2026

Remaining vesting schedule 10 quarterly installments After November 18, 2026, subject to continuous service

Grant price per share $0.0000 per share Compensation grant, not open-market purchase

Key Terms

restricted stock units ("RSUs"), contingent right, vest, continuous service

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vest financial

"16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continuous service financial

"in each case subject to the Reporting Person's continuous service through each such vesting date."

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		A⁽¹⁾		49,830	A	$0	82,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Mary Miller?

Acrivon Therapeutics reported that Chief Legal Officer Mary Miller received 49,830 restricted stock units. These RSUs are a compensation grant, not an open-market purchase, and each unit represents a right to receive one share of Acrivon’s Common Stock if service-based vesting conditions are met.

How many Acrivon (ACRV) shares does Mary Miller hold after this Form 4?

After the RSU grant, Mary Miller is reported as directly holding 82,767 shares of Acrivon Common Stock. This total includes the 49,830 newly granted RSUs, which convert into shares only as they vest over time, subject to her continued service with the company.

How do the Acrivon (ACRV) RSUs granted to Mary Miller vest?

The RSUs granted to Mary Miller vest in stages. The filing states that 16.67% of the restricted stock units vest on November 18, 2026, and the remaining units vest in 10 substantially equal quarterly installments, assuming she continues providing service through each scheduled vesting date.

Did Mary Miller buy or sell Acrivon (ACRV) stock in this Form 4?

Mary Miller did not buy or sell shares on the open market in this filing. Instead, she acquired 49,830 restricted stock units as a grant with a reported price per share of $0.0000, reflecting a compensation award rather than a market transaction involving cash consideration.

What does each Acrivon (ACRV) RSU granted to Mary Miller represent?

Each RSU granted to Mary Miller represents a contingent right to receive one share of Acrivon’s Common Stock. The rights only convert into actual shares if the specified vesting schedule is satisfied and she maintains continuous service through each relevant vesting date described in the disclosure.